Opportunities Map in the Acquisition Arena

Opportunities Map for LPBI Group’s three Intellectual Property Asset Classes of Digital Published Products in the Acquisition Arena

The intellectual property of LPBI is of three types: a corpus of curated articles, a corpus of e-books, and a corpus of e-proceedings. This IP is highly relevant to five industries across twelve economic sectors. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI and can be represented as such to potential investors. Together with the tangible assets described below, the combination represents a unique opportunity for acquisition.

Value Drivers
Business Functions
Economic Sectors

Potential Acquirers in Five Economic Sectors and Industries: Financial Sector, Information Technology (IT) Companies, Manufacturing, Education: Private & Public Institutions and Media by Business Function Type & Value Drivers of Three Asset Classes available for Potential Use by Acquirers

List of IP Assets – DIGITAL PUBLISHED PRODUCTS for Technology Transfer of Ownership:

IP Asset Class I: The Journal +5,500 Scientific articles

https://lnkd.in/erfbayJ

IP Asset Class II: 16 Volumes in BioMed e-Series

https://lnkd.in/ekWGNqA

IP Asset Class III: +60 eProceedings of BioTech & Medical Conferences

https://pharmaceuticalintelligence.com/press-coverage/

Business Function	Value Drivers	FINANCIAL SECTOR		INFORMATION TECHNOLOGY
Business Function	Value Drivers	Holding Companies & Investment Bankers	Health Care Insurers	Cloud-based	Cloud & Server-based
Product Marketing	Revenue generation by pene- tration of multiple markets simulta- neously, exploit economic benefits from internal vertical integration, product differentiation and diversification across product lines and markets	Internet Brands of KKR, Temasek, NMC, Generex
Product Development	(a) Software Application development (b) product repurposing (c) Beta Testing or Clinical Trials			Amazon Web Services (AWS), Alphabet – Verily, Apple-Health, IBM Watson	Microsoft, Oracle-Health, SAAP
Horizontal Merger	Change in Organizational Structure by acquiring economies of scale and increasing capacities for doing same functions in bigger scale
Vertical Merger	Change in Organization Structure by integration of additional functionality to existing workflows & production processes, capability augmentation by new expertise (R&D, Production, Marketing) via acquisitions
Application of proprietary Intellectual Property & Knowledge dissemination to Members or event Attendees	Creative scientific CONTENT creation
Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding	Cost containment by new efficiencies		United Health, Kaiser Perma-nente & BlueCross/ BlueShield

Business Function	Value Drivers	MANUFACTURING
Business Function	Value Drivers	Big Pharma Drug Production	Scientific Publishing Journals & Book Production
Product Marketing	Revenue generation by penetration of multiple markets simultaneously, exploit economic benefits from internal vertical integration, product differentiation and diversification across product lines and markets
Product Development	(a) Software Application development (b) product repurposing (c) Beta Testing or Clinical Trials	J&J, Roche, Novartis, Pfizer, Bayer, Merck, GSK, Sanofi, Abbvie, Abbott, Eli Lilly, Amgen, BMS, Gilead, AstraZeneca, TEVA, BI, NovoNordisk, Allergen, Takeda, Shire, Celgene, Biogen
Horizontal Merger	Change in Organizational Structure by acquiring economies of scale and increasing capacities for doing same functions in bigger scale		Wolters Kluwer, Elsevier, John Wiley, CHI
Vertical Merger	Change in Organization Structure by integration of additional functionality to existing workflows & production processes, capability augmentation by new expertise (R&D, Production, Marketing) via acquisitions	J&J, Roche, Novartis, Pfizer, Bayer, Merck, GSK, Sanofi, Abbvie, Abbott, Eli Lilly, Amgen, BMS, Gilead, AstraZeneca, TEVA, BI, NovoNordisk, Allergen, Takeda, Shire, Celgene, Biogen
Application of proprietary Intellectual Property & Knowledge dissemination to Members or event Attendees	Creative scientific CONTENT creation
Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding	Cost containment by new efficiencies

Business Function	Value Drivers	EDUCATION Private & Public Institutions		MEDIA
Business Function	Value Drivers	Medical Education	Online Certifi-cations and Degrees	Health Care Services (Contract-based Out-sourcing)	Content -driven
Product Marketing	Revenue generation by penetration of multiple markets simulta-neously, exploit economic benefits from internal vertical integration, product differentiation and diversifi-cation across product lines and markets
Product Development	(a) Software Application development (b) product repurposing (c) Beta Testing or Clinical Trials				(b) Infor- mation Syndica tors (Reuters Clarivate & Springer)
Horizontal Merger	Change in Organizational Structure by acquiring economies of scale and increasing capacities for doing same functions in bigger scale				(d) Internet Health Care Media (MedScape, UptoDate)
Vertical Merger	Change in Organization Structure by integration of additional functionality to existing workflows & production processes, capability augmentation by new expertise (R&D, Production, Marketing) via acquisitions
Application of proprietary Intellectual Property & Knowledge dissemi-nation to Members or event Attendees	Creative scientific CONTENT creation	250 Medical Schools in the US & Medical Schools in the European Community	Coursera & MOOC		(c) Medical and Pharma Associations (a) Global Biotech & Pharma-ceutical Conference Organizers
Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding	Cost containment by new efficiencies			Top 10 on List of Global and US-based CRO & CRA

Three IP Asset Classes: Their Economic Value Potential for

Prospective acquirers

Holding Company and Investment Banker

Potential Use by Acquirer:

Invest in product marketing of three Lines of Business

Class I,II,III

Internet Brands of KKR

http://www.kkr.com/

Temasek

https://www.temasek.com.sg/en/index.html

http://www.newmountaincapital.com/

Generex

http://www.generex.com/

Information Technology Companies – Health Care

Potential Use by Acquirer:

Use contents in application development

Class I,II,III

Amazon Web Services (AWS)
Google- Verily
Apple Health
Microsoft
IBM-Watson
Oracle Healthcare

Scientific Publishers

Potential Use by Acquirer:

Horizontal merger

Class I,II,III

Wolters Kluwer
Elsevier
John Wiley
CHI

Big Pharma

Potential Use by Acquirer:

Vertical Integration with a production factor

Class I,II,III

1. Drug Discovery Process

2. Clinical Trial

3. Drug Repurposing

https://pharmaceuticalintelligence.com/2019/02/14/drug-repurposing-hub-library-broadinstitute-mit-harvard/

J&J
Roche
Novartis
Pfizer
Bayer
Merck
GSK
Sanofi
Abbvie
Abbott
Eli Lilly
Amgen
BMS
Gilead
AstraZeneca
TEVA
BI
NovoNordisk
Allergen
Takeda
Shire
Celgene
Biogen

Internet Health Care Media

Potential Use by Acquirer:

Horizontal merger

Class I,II,III

MedScape

– 676,000 active US Physicians

– 2,000,000 active US HCP’s (non-Physicians)

UptoDate

Education

Potential Use by Acquirer:

Content is King

Class I,II

MOOC
Coursera

Health Insurance Companies & HMOs

Potential Use by Acquirer:

Optimization of Treatment: Efficacy vs cost of treatment

Class I,II,III

United Health
Kaiser Permanente
BC/BS

Medical and Pharma Associations

Potential Use by Acquirer:

Information for Members

Class I,II,III

Chinese College of Cardiology – 350,000 MDs
Chinese College of Oncology
Germany
Japan
India
Canada

Medical Education

Potential Use by Acquirer:

Content is King

Class I,II,III

250 Medical Schools in the US
Europe

In 2019, Class II, e-Books are in Use in Medical Schools in the State of Pennsylvania for curriculum development:

Series A: Volume 3 – Epigenetics, Genetics and Genomics [Jefferson Medical School, Philadelphia]

Series B: Volume 1 – Genomics & Personalized Medicine [Temple University, Philadelphia]

Series C: Volume 1,2 – Cancer [Temple University, Philadelphia]

Series E: Volume 1 – Voices of Patients [Jefferson Medical School, Philadelphia]

Information Syndicators

Potential Use by Acquirer:

Text Mining

Class I,II,III

US – Reuters’ Clarivate

They are operating in the same arena.

They can use our system to other domains.

They can develop it as part of their comprehensive offer.

New connections and ideas they will bring on board.

Europe – Springer

Global Biotech & Pharmaceutical Conference Organizers

Potential Use by Acquirer:

Information for Attendees

Class I,II,III

CRO & CRA

Potential Use by Acquirer:

Text Mining for Indication and off label in Clinical Trial Design and After Market Efficacy Monitoring

Class I,II,III

Top 10 on List of CRO in the US
Top 10 on List of Global CRO

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com